Clinical trial · Interventional
Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain
Study of the Effectiveness of Ultrasound-guided Percutaneous Neuromodulation Versus Pharmacological Treatment in Oncology Patients With Anterior Knee Pain
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study not initiated prior to enrollment.
Summary
Brief summary (as posted)
the goal of this clinical trial is to compare in cancer patients: Is ultrasound-guided percutaneous neuromodulation useful for Anterior Knee Pain relief in cancer patients? Participants will receive treatments of ultrasound-guided percutaneous neuromodulation and pharmacological treatment Researchers will compare ultrasound-guided percutaneous neuromodulation versus pharmacological treatment to see if Anterior Knee Pain is reduced
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pain Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pharmacological treatment by Opioids | Drug | — | UNRESOLVED |
| Ultrasound-guided percutaneous neuromodulation (NMP) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Epte Bipolar System 2.0 - Ultrasound-guided percutaneous neuromodulation (NMP)
- description
- Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. Ultrasound-guided percutaneous neuromodulation (NMP)
- interventionNames
- Device: Ultrasound-guided percutaneous neuromodulation (NMP)
- type
- EXPERIMENTAL
- label
- pharmacological treatment by Opioids
- description
- Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects. Tramadol (Ultram®) Hydromorphone (Dilaudid®) Methadone (Dolophine®, Methadose®) Morphine (Apokyn®, Avinza®, Kadian®, MS-Contin®, among others) Oxycodone (OxyContin®, OxyIR®, Roxicodone®) Hydrocodone Oxymorphone (Opana®) Fentanyl (Actiq®, Duragesic®, Fentora®, Lazanda®, Subsys®, and others) Tapentadol (Nucynta®)
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: The proposed inclusion criteria for the study are as follows: * Age between 18 and 65. * Pain in the front of the knee. * Taking drug therapy for lower-extremity pain. * Diagnosis of painful pathology in the anterior aspect of the knee secondary oncologic. Exclusion Criteria: The exclusion criteria are: * Traumatic history * Have had any type of analgesic treatment in the last 4 weeks (clinical, physical or orthostatic) * No need for drug treatment within the last 30 days of study initiation.
References
Publications (0)
Data not yet available